Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality

By Chi Zhang, Zhao Wu, Jiawen Li, Hong Zhao, Guiqiang Wang. International Journal of Antimicrobial Agents, 2020

1,480 citations recorded by the source corpus.

Highlights • Pathogenesis of cytokine release syndrome (CRS) in severe COVID-19 patients.• Key role of interleukin-6 (IL-6) in CRS.• IL-6 receptor (IL-6R) antagonist tocilizumab suggested as a possible drug for severe COVID-19.

Subfields: Infectious Diseases, Molecular Biology, Neurology

View Paper: https://www.semanticscholar.org/paper/62fe86bbb98fcbbf0b4838abbb15cb3d95471e57